European Association of Dermato-Oncology 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024
Include: 26 videos + 1 pdf, size: 21.1 GBTarget Audience: dermatologists, oncologists, pathologists
Information:
The 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024 is an interdisciplinary global conference focused on the latest advancements in melanoma and skin cancer. It will take place on June 27–28, 2024, at the Hilton Hotel Munich Park, Germany.
Key Details:
- Format: Hybrid (In-person & Virtual)
- Congress Presidents: Axel Hauschild (Kiel, Germany) & Claus Garbe (Tuebingen, Germany)
-
Topics Covered:
- Results and interpretations of ASCO 2024 presentations
- Adverse event management for targeted and immunotherapies
- Gut microbiome and its role in immuno-oncology
- Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas
- Neoadjuvant vs. perioperative immune checkpoint inhibitors (ICI)
- Cutaneous T-cell lymphoma (CTCL)
- Adjuvant treatment of melanoma
- Interactive case discussions on complex melanoma and non-melanoma cases
This meeting provides a comprehensive overview of new developments in melanoma diagnostics, drug development, and clinical trials, fostering interaction between clinicians, researchers, and industry experts
The 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024 is designed for medical professionals specializing in melanoma and skin cancer treatment. The target audience includes:
- Dermatologists and oncologists focused on melanoma and skin cancer.
- Clinical researchers involved in melanoma diagnostics and therapy.
- Pathologists specializing in skin cancer histopathology.
- Medical professionals interested in immuno-oncology and targeted therapies.
- Industry experts working on drug development and clinical trials.
This interdisciplinary conference provides a comprehensive overview of the latest advancements in melanoma diagnostics, treatment strategies, and emerging therapies. It fosters direct communication between clinicians, researchers, and industry representatives
Topics:
- 16_EPCM-2024_FINAL-Program_web.pdf
CLOSING REMARKS.mp4
KEYNOTE LECTURE I.mp4
KEYNOTE LECTURE II.mp4
KEYNOTE LECTURE III.mp4
KEYNOTE LECTURE IV.mp4
OPENING OF THE CONFERENCE.mp4
PARALLEL SYMPOSIUM I Adverse event management of targeted and immunotherapies.mp4
PARALLEL SYMPOSIUM II Real world evidence studies from registries.mp4
PARALLEL SYMPOSIUM III Cutaneous T-cell lymphoma (CTCL).mp4
PARALLEL SYMPOSIUM IV Interactive Discussion of complex melanoma cases.mp4
PARALLEL SYMPOSIUM V Interactive Discussion of complex non-melanoma cases.mp4
PARALLEL SYMPOSIUM VI Innovative therapies for orphan diseases.mp4
SATELLITE SYMPOSIUM I NOVARTIS Gold Sponsor Yesterday, Today & Tomorrow Long-Term Benefits with Targeted Therapy in Adjuvant Melanoma.mp4
SATELLITE SYMPOSIUM II BMS Gold Sponsor IO-Combinations in Melanoma- How to Proceed – Less or More.mp4
SATELLITE SYMPOSIUM III MSD Platinum Sponsor Advancements in Early Melanoma Integrating Recent Updates into Clinical Practice.mp4
SATELLITE SYMPOSIUM V REGENERON Platinum Sponsor Evolving Perspectives on Treatment Roadmap for Advanced Non-melanoma Skin Cancer.mp4
SATELLITE SYMPOSIUM VI PHILOGEN Sponsor Novel treatments for locally advanced skin cancers.mp4
SATELLITE SYMPOSIUM VII MERCK Bronze Sponsor Leveraging Real-World Evidence in Advanced Merkel Cell Carcinoma- Insights from Clinical Practice.mp4
SYMPOSIUM I My personal highlights at ASCO 2024.mp4
SYMPOSIUM II Which vaccines work and which not.mp4
SYMPOSIUM III The role of gut microbiome for immunooncology.mp4
SYMPOSIUM IV Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas (unrestricted Educational Grant Immunocore).mp4
SYMPOSIUM V Controversy- Is neoadjuvant or perioperative ICI already standard of care.mp4
SYMPOSIUM VI Adjuvant treatment of melanoma.mp4
SYMPOSIUM VII Intralesional therapies for melanoma and NMSC.mp4
SYMPOSIUM VIII What’s new in NMSC Publication highlights from the last 12 months.mp4
